White Paper

Bringing The Freezing Of Biopharmaceuticals In From The Cold

Source: Cytiva
covid vial cold chain iStock-1293941660

With 59.4% of manufactured drug substances being in a frozen state prior to shipping, it is not surprising that over recent years freeze-thaw technology has been scrutinized for efficiency, not only for the physical act of freezing and the effect it may have, but also the processes surrounding it – filling, storing, transporting, thawing and traceability. It is paramount that high value product – both in terms of money and patient safety – is given priority so that it can reach patients quickly, while maintaining the safety, efficacy and activity profile, using economically sound processes and technologies. With this in mind, the conventional static freezing methods need to be weighed against the potential advantages of alternative approaches such as plate freezing technology.

Do we dare treat drug substance freezing as an isolated process? Or should freezing be integrated with bulk filling, storage, shipping, thawing and fill-finish operations to deliver a multi-site end-to-end process that is inherently seamless and equally capable of assuring consistent product quality and safeguarding valuable product? In this paper review integrated solutions to minimize risk and preserve product quality.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online